Groups
Publications
-
Matos, AI; Peres, C; Carreira, B; Moura, LIF; Acurcio, RC; Vogel, T; Wegener, E; Ribeiro, F; Afonso, MB; Santos, FMF; Martínez-Barriocanal, A; Arango, D; Viana, AS; Góis, PMP; Silva, LC; Rodrigues, CMP; Graca, L; Jordan, R; Satchi-Fainaro, R; Florindo, HF
Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors
Advanced Science 10 -. .
-
Carton-Garcia, F; Brotons, B; Anguita, E; Dopeso, H; Tarragona, J; Nieto, R; Garcia-Vidal, E; Macaya, I; Zagyva, Z; Dalmau, M; Sanchez-Martin, M; van Ijzendoorn SCD; Landolfi, S; Hernandez-Losa, J; Schwartz S Jr; Matias-Guiu, X; Ramón Y Cajal S; Martinez-Barriocanal, A; Arango, D
Myosin Vb as a tumor suppressor gene in intestinal cancer.
ONCOGENE 41 5279-5288. .
-
Fourniols, T; Maggio, V; Rafael, D; Colaco, A; García Vidal E; Lopes, A; Schwartz, S; Martinez-Barriocanal, A; Preat, V; Arango, D
Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS 171 39-49. .
-
Bazzocco S; Dopeso H; Martínez-Barriocanal Á; Anguita E; Nieto R; Li J; García-Vidal E; Maggio V; Rodrigues P; de Marcondes PG; Schwartz S Jr; Aaltonen LA; Sánchez A; Mariadason JM; Arango D
Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis.
Clinical Epigenetics 13 88-88. .
-
Montanuy, H; Martinez-Barriocanal, A; Antonio Casado J; Rovirosa, L; Ramirez, MJ; Nieto, R; Carrascoso-Rubio, C; Riera, P; Gonzalez, A; Lerma, E; Lasa, A; Carreras-Puigvert, J; Helleday, T; Bueren, JA; Arango, D; Minguillon, J; Surralles, J
Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer.
CLINICAL CANCER RESEARCH 26 3044-3057. .
-
Martinez-Barriocanal, A; Arango, D; Dopeso, H
PVT1 Long Non-coding RNA in Gastrointestinal Cancer.
Frontiers in oncology 10 38-38. .
-
Matos AI; Carreira B; Peres C; Moura LIF; Conniot J; Fourniols T; Scomparin A; Martínez-Barriocanal Á; Arango D; Conde JP; Préat V; Satchi-Fainaro R; Florindo HF
Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer.
JOURNAL OF CONTROLLED RELEASE 307 108-138. .
Projects
- Turning drug-induced senescence into a novel therapeutic opportunity for colorrectal cancer treatment
- Nueva aproximación terapéutica para el cáncer colorectal.
- EPH Receptor Signaling in Endometrial Cancer
- Antioxidant treatment as a novel therapeutic option for microvillus inclusion disease. ARMED
- Nueva estrategia terapéutica para ael cáncer gástrico basada en la modulación de la señalización de RHOA
- Desarrollo de nanosistemas de marcaje de CXCR4 mediante radiosondas para la imagen molecular de células tumorales y del microambiente tumoral
- Identificación de nuevos biomarcadores de respuesta a los compuestos regorafenib y TAS-102 en pacientes con cáncer colorrectal.
- Targeting tumor microevironment by a translational multivalent nanomedicine: towards an effective anticancer combination immunotherapy
